Equities research analysts expect that Qiagen (NASDAQ:QGEN – Get Rating) will post earnings of $0.45 per share for the current quarter, according to Zacks. Three analysts have issued estimates for Qiagen’s earnings. The highest EPS estimate is $0.49 and the lowest is $0.44. Qiagen posted earnings of $0.67 per share during the same quarter last year, which would indicate a negative year over year growth rate of 32.8%. The firm is scheduled to report its next earnings results on Monday, January 1st.
On average, analysts expect that Qiagen will report full-year earnings of $2.10 per share for the current fiscal year, with EPS estimates ranging from $2.05 to $2.22. For the next year, analysts expect that the company will report earnings of $2.16 per share, with EPS estimates ranging from $2.08 to $2.23. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Qiagen.
Separately, StockNews.com started coverage on Qiagen in a report on Thursday, March 31st. They issued a “strong-buy” rating on the stock.
About Qiagen (Get Rating)
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
- Get a free copy of the StockNews.com research report on Qiagen (QGEN)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.